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Objectives This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial
fibrillation (AF) treated with warfarin or rivaroxaban.
Background There are limited data on outcomes following cardioversion or catheter ablation in AF patients treated with fac-
tor Xa inhibitors.
Methods We compared the incidence of electrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation
and subsequent outcomes in patients in a post hoc analysis of the ROCKET AF (Efficacy and Safety Study of Ri-
varoxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in
Patients With Non-Valvular Atrial Fibrillation) trial.
Results Over a median follow-up of 2.1 years, 143 patients underwent ECV, 142 underwent PCV, and 79 underwent
catheter ablation. The overall incidence of ECV, PCV, or AF ablation was 1.45 per 100 patient-years (n  321;
1.44 [n  161] in the warfarin arm, 1.46 [n  160] in the rivaroxaban arm). The crude rates of stroke and
death increased in the first 30 days after cardioversion or ablation. After adjustment for baseline differences,
the long-term incidence of stroke or systemic embolism (hazard ratio [HR]: 1.38; 95% confidence interval [CI]:
0.61 to 3.11), cardiovascular death (HR: 1.57; 95% CI: 0.69 to 3.55), and death from all causes (HR: 1.75; 95%
CI: 0.90 to 3.42) were not different before and after cardioversion or AF ablation. Hospitalization increased after
cardioversion or AF ablation (HR: 2.01; 95% CI: 1.51 to 2.68), but there was no evidence of a differential effect
by randomized treatment (p value for interaction  0.58). The incidence of stroke or systemic embolism (1.88%
vs. 1.86%) and death (1.88% vs. 3.73%) were similar in the rivaroxaban-treated and warfarin-treated groups.
Conclusions Despite an increase in hospitalization, there were no differences in long-term stroke rates or survival following
cardioversion or AF ablation. Outcomes were similar in patients treated with rivaroxaban or warfarin. (An Efficacy
and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System
Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation [ROCKET AF]; NCT00403767) (J Am Coll
Cardiol 2013;61:1998–2006) © 2013 by the American College of Cardiology Foundation
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May 14, 2013:1998–2006 Outcomes After Cardioversion and Atrial Fibrillation With RivaroxabanPatients with atrial fibrillation (AF) often require cardio-
version or ablation for symptom control (1). Periprocedural
management of oral anticoagulation and stroke prevention
is challenging yet important given the increased risk of
thrombotic events following restoration of sinus rhythm (2).
While clinical trials and guidelines address the management
of vitamin K antagonists before and after these procedures,
there are limited data regarding the use of novel oral
anticoagulants, including factor Xa inhibitors (3). The
ROCKET AF (Rivaroxaban Once-daily, oral, direct Factor Xa
inhibition Compared with vitamin K antagonism for pre-
vention of stroke and Embolism Trial in Atrial Fibrillation)
study was an international, randomized, double-blind,
double-dummy, event-driven noninferiority trial comparing
fixed-dose rivaroxaban (20 mg daily; 15 mg daily in patients
with creatinine clearance of 30 to 49 ml/min) with dose-
adjusted warfarin (target international normalized ratio
[INR]: 2.0 to 3.0) for the prevention of stroke or non-
central nervous system (CNS) embolism in patients with
non-valvular AF at moderate or high risk of stroke (4). In
14,264 patients over a median follow-up of 707 days,
once-daily rivaroxaban therapy was shown to be noninferior
to dose-adjusted warfarin, with less intracranial and fatal
bleeding. The goal of this post-hoc analysis was to describe
the incidence, predictors, and outcomes associated with
cardioversion and catheter ablation in patients treated with
warfarin and rivaroxaban in the ROCKET AF trial.
Methods
The rationale and design of the ROCKET AF study have
been published previously (NCT00403767) (5). Briefly, the
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center, international, double-blind,
double-dummy, randomized trial
comparing fixed-dose rivaroxa-
ban with adjusted-dose warfarin
for prevention of all strokes (isch-
emic or hemorrhagic) or systemic
embolism. The study was funded
by Johnson & Johnson Pharma-
ceutical Research and Develop-
ment (Raritan, New Jersey) and
Bayer HealthCare AG (Le-
verkusen, Germany). The Duke
Clinical Research Institute (Dur-
ham, North Carolina) coordinated
the trial and performed the statistical analyses for the manu-
script independent of the sponsors. An international executive
committee designed the study and took responsibility for the
accuracy and completeness of the analyses. All appropriate
national regulatory authorities and ethics committees at par-
ticipating centers approved the study.
Definitions, endpoints, and baseline variables. Patients
were evaluated at a minimum of every 4 weeks throughout
the trial for study drug management, ascertainment of
adverse events, and surveillance for the primary endpoints
and other clinical events. Procedures to treat AF were
captured in case report form. Sites were instructed to record
all AF ablations (surgical or catheter-based), electrical
cardioversions (ECV), and pharmacologic cardioversions
(PCV), including the dates of the procedures. PCV in-
cluded both intravenous and oral administration of antiar-
rhythmic medications for the purpose of cardioversion. The
use of transesophageal echocardiography was not captured
in the case report form.
The interventions of interest in this analysis were ECV,
PCV, and AF ablation as well as the composite of all
cardioversions (ECV or PCV), and the composite of all
cardioversions and AF ablations (ECV, PCV, or AF abla-
tion) in those patients who were randomized and took one
or more doses of the study drug. The primary efficacy
endpoint in ROCKET AF was the composite of all strokes
(both ischemic and hemorrhagic) and systemic embolism. A
full description of the endpoints in ROCKET AF has been
published previously (5). Secondary efficacy endpoints in-
cluded cardiovascular (CV) death, all-cause death, the
composite of stroke, systemic embolism, or CV death, and
the composite of stroke, systemic embolism, or all-cause
death. We also analyzed all hospitalizations. The safety
endpoint was major or non-major clinically relevant bleed-
ing. All suspected primary endpoint events and causes of
death were adjudicated by an independent clinical endpoint
committee. Rates of cardioversion or AF ablation among all
ROCKET patients in the safety on-treatment population
are presented as events per 100 patient-years of follow-up
and total number of events. Rates of endpoints among
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
CNS  central nervous
system
ECV  electrical
cardioversion
HR  hazard ratio
PCV  pharmacologic
cardioversion
TIA  transient ischemic
attackpatients with cardioversion or AF ablation are presented as
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Outcomes After Cardioversion and Atrial Fibrillation With Rivaroxaban May 14, 2013:1998–2006Baseline Characteristics According to Cardioversion (Electricaland Pharmacologic) or Catheter Ablation and Randomiz d TreatmentTable 1 B seline Chara teristics According to Cardiove sion (Electricaland Pharmacologic) or Catheter Ablation and Randomized Treatment
ECV, PCV, or Ablation No ECV, PCV, or Ablation
Characteristic
Rivaroxaban
(n  160)
Warfarin
(n  161)
Rivaroxaban
(n  6,901)
Warfarin
(n  6,921)
Age, yrs 68.5 (61.5, 75) 71 (62, 76) 73 (65, 78) 73 (65, 78)
Male 66 (41.3) 59 (36.6) 2,725 (39.5) 2,740 (39.6)
Race
White 146 (91.3) 157 (97.5) 5,710 (82.7) 5,752 (83.1)
Black 3 (1.9) 1 (0.6) 91 (1.3) 84 (1.2)
Asian 4 (2.5) 2 (1.2) 890 (12.9) 885 (12.8)
Other 7 (4.4) 1 (0.6) 210 (3.0) 200 (2.9)
Hispanic or Latino 12 (7.5) 12 (7.5) 1,149 (16.6) 1,155 (16.7)
Region
Western Europe 34 (21.3) 32 (19.9) 1,006 (14.6) 1,017 (14.7)
Asia/Pacific Islands 4 (2.5) 4 (2.5) 1,048 (15.2) 1,048 (15.1)
Eastern Europe 65 (40.6) 74 (46.0) 2,631 (38.1) 2,630 (38.0)
Latin America 4 (2.5) 6 (3.7) 935 (13.5) 932 (13.5)
North America 53 (33.1) 45 (28.0) 1,281 (18.6) 1,294 (18.7)
CHADS2 score 3 (3, 4) 3 (3, 4) 3 (3, 4) 3 (3, 4)
BMI (kg/m2) 29.4 (26.6, 32.9) 28.4 (26.1, 32.8) 28.3 (25.1, 32.1) 28.1 (25.1, 31.8)
Heart rate (beats/min) 70.5 (62, 86) 72 (64, 82.5) 76 (68, 85) 76 (67, 86)
Systolic BP (mm Hg) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140)
Diastolic BP (mm Hg) 80 (72, 83) 80 (70.5, 83) 80 (70, 85) 80 (70, 85)
Type of AF
Persistent 79 (49.4) 75 (46.6) 5,660 (82.0) 5,648 (81.6)
Paroxysmal 76 (47.5) 81 (50.3) 1,152 (16.7) 1,178 (17.0)
New 5 (3.1) 5 (3.1) 89 (1.3) 95 (1.4)
LBBB 13 (8.2) 13 (8.2) 462 (6.7) 477 (6.9)
History of stroke or TIA 82 (51.3) 87 (54.0) 3,640 (52.7) 3,605 (52.1)
History of hypertension 148 (92.5) 146 (90.7) 6,224 (90.2) 6,283 (90.8)
History of CHF 91 (56.9) 98 (60.9) 4,337 (62.9) 4,311 (62.3)
History of diabetes 64 (40.0) 61 (37.9) 2,778 (40.3) 2,732 (39.5)
History of COPD 16 (10.0) 15 (9.3) 728 (10.6) 718 (10.4)
History of GI bleeding 9 (5.6) 8 (5.0) 216 (3.1) 263 (3.8)
History of liver disease 11 (6.9) 8 (5.0) 358 (5.2) 363 (5.2)
Vascular disease indicator for CHA2DS2VASC 40 (25.0) 45 (28.0) 1,532 (22.2) 1,669 (24.1)
History of sleep apnea 14 (8.8) 12 (7.5) 307 (4.4) 312 (4.5)
History of cigarette smoking 68 (42.5) 60 (37.3) 2,371 (34.4) 2,250 (32.5)
Alcohol consumption in last 12 months
None 100 (62.5) 96 (59.6) 4,448 (64.5) 4,494 (64.9)
Light 54 (33.8) 60 (37.3) 2,098 (30.4) 2,080 (30.1)
Moderate 6 (3.8) 4 (2.5) 300 (4.3) 299 (4.3)
Heavy 0 (0) 1 (0.6) 55 (0.8) 47 (0.7)
Aspirin 47 (29.4) 41 (25.5) 1,983 (28.7) 2,027 (29.3)
Thienopyridine 7 (4.4) 4 (2.5) 104 (1.5) 123 (1.8)
VKA 102 (63.8) 115 (71.4) 4,299 (62.3) 4,322 (62.4)
ACE inhibitor/ARB 127 (79.4) 120 (74.5) 5,160 (74.8) 5,121 (74.0)
Beta blocker 123 (76.9) 120 (74.5) 4,438 (64.3) 4,503 (65.1)
Amiodarone 35 (21.9) 27 (16.8) 538 (7.8) 542 (7.8)
Digoxin 33 (20.6) 36 (22.4) 2,689 (39.0) 2,702 (39.0)
Sotalol 19 (11.9) 18 (11.2) 127 (1.8) 123 (1.8)
Lipid lowering 83 (51.9) 93 (57.8) 2,936 (42.5) 2,951 (42.6)
CCB 55 (34.4) 48 (29.8) 1,946 (28.2) 1,884 (27.2)
Other antiarrhythmic drugs 12 (7.5) 15 (9.3) 156 (2.3) 126 (1.8)
Anemia (Hb 13 in men; Hb 12 in women) 24 (15.2) 16 (10.5) 944 (14.0) 980 (14.4)
Platelets (109/l) 219 (182, 262) 209 (178, 254) 221 (184, 265) 222 (184, 265)Continued on the next page
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May 14, 2013:1998–2006 Outcomes After Cardioversion and Atrial Fibrillation With Rivaroxabanthe number of events during the time period divided by the
number of patients at risk.
Statistical analysis. Baseline characteristics were summa-
rized numerically for categorical variables and as median
values with 25th and 75th percentiles for continuous vari-
ables, according to the occurrence of ECV, PCV, or AF
ablation and according to randomized treatment assign-
ment. Event rates per 100 patient-years of follow-up and
the total number of events while on treatment during the
trial were presented for the following endpoints: 1) ECV;
2) PCV; 3) AF ablation; and 4) any ECV, PCV, or AF
ablation. Cumulative incidence plots for ECV/PCV/AF
ablation with all-cause death as competing risk were pre-
sented. Event rates and cumulative incidence plots were
repeated for the cardioversion and ablation endpoints strat-
ified by region or randomized treatment. The relationships
between region or treatment and intervention were charac-
terized using hazard ratios (HR) and corresponding 95%
confidence intervals (CI) from a Cox proportional hazards
model. Region and treatment were the only covariates
included in the model, where the reference groups were
Western Europe and warfarin, respectively.
Cox proportional hazards models were used to identify
factors associated with ECV, PCV, or AF ablation and
ECV or PCV during follow-up. Twenty-four covariates
recorded at randomization were considered for inclusion
in the model for prediction of ECV, PCV, and AF
ablation: age, sex, race, ethnicity, region, heart rate, body
mass index, systolic blood pressure, diastolic blood pres-
sure, type of AF (persistent, paroxysmal, recent onset),
prior stroke or transient ischemic attack (TIA), heart
failure, hypertension, diabetes mellitus, coronary artery
disease (history of myocardial infarction, percutaneous
coronary intervention, or coronary artery bypass graft-
ing), creatinine clearance, peripheral arterial disease,
chronic obstructive pulmonary disease, carotid athero-
sclerosis, prior gastrointestinal bleeding, liver disease,
alcohol use, obstructive sleep apnea, and left bundle
branch block. Heart failure was defined as a clinical
ContinuedTable 1 Continued
ECV
Characteristic
Rivaroxa
(n  16
CrCl (Cockcroft-Gault), (ml/min/1.73 m2) 75 (56, 1
Albumin (g/dl) 4.0 (3.8, 4
SGOT/AST (U/l) 22 (19, 2
SGPT/ALT (U/l) 21 (17, 3
Total bilirubin (mg/dl) 0.5 (0.4, 0
Serum glucose (mg/dl) 106 (96.5,
Values are median (25th, 75th percentile) or n (%).
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; ALT
aspartate aminotransferase; BMI  body mass index; BP  blood p
COPD chronic obstructive pulmonary disease; CrCl creatinine clear
LBBB left bundle branch block; PCV pharmacologic cardioversion
pyruvate transaminase; TIA  transient ischemic attack; VKA  vitamdiagnosis of heart failure or a left ventricular ejection (fraction 35%. The CHADS2 risk scores were derived from
aseline covariates (6). Consistent with the CHA2DS2VASC
isk stratification scheme, coronary, carotid, and periph-
ral arterial disease were combined as a single variable
ermed vascular disease (7). Creatinine clearance was
alculated using the Cockcroft-Gault formula (8,9). We
ested the proportional hazards assumption and the
lobal tests of proportional hazards were not significant. In
he multivariable model, covariates were selected stepwise
alpha 0.05 to enter and retain). Associations are reported
s HRs with 95% CIs.
To investigate the associations among ECV/PCV/AF
blation and the long-term outcomes, Cox regression mod-
ls were fitted with ECV/PCV/AF ablation as a time-
ependent variable. All models were adjusted for sex, age,
iastolic blood pressure, and chronic obstructive pulmonary
isease. Additionally, efficacy models were adjusted for prior
troke or TIA, estimated glomerular filtration rate, vascular
isease, type of AF, heart rate, congestive heart failure, body
ass index, region, alcohol use, diabetes, and creatinine; the
leeding model additionally was adjusted for gastrointesti-
al bleeding, aspirin, and anemia. Models assume there are
o time-dependent covariates that could be associated with
oth ECV/PCV/AF ablation and outcomes. Only the first
ntervention per patient was included. HR estimates with
5% CIs were presented. For the endpoints of hospitaliza-
ion and major or non-major clinically relevant bleeding,
ifferences in association by randomized treatment were
nvestigated by including terms for treatment (rivaroxaban
r warfarin), the intervention of interest (ECV/PCV/AF
blation) as a time-dependent variable, and the interaction
n the model. Separate HR estimates and 95% CIs were
resented for each treatment only if the interaction term was
ignificant at the 0.05 level. For other efficacy endpoints, the
nteraction of treatment and ECV/PCV/AF was not inves-
igated because of the low event counts. Events in the 30
ays following cardioversion or ablation were summarized
ut were not modeled due to the small number of events. All
nalyses were performed using SAS version 9.2 software
or Ablation No ECV, PCV, or Ablation
Warfarin
(n  161)
Rivaroxaban
(n  6,901)
Warfarin
(n  6,921)
71 (56, 99) 67 (52, 87) 67 (52, 86)
4.0 (3.8, 4.2) 4.0 (3.8, 4.2) 4.0 (3.8, 4.2)
22 (19, 28) 23 (19, 28) 23 (19, 28)
24 (17, 34) 21 (16, 28) 21 (16, 28)
0.5 (0.4, 0.8) 0.6 (0.4, 0.8) 0.6 (0.4, 0.8)
106 (97, 128) 107 (95, 135) 108 (95, 135)
nine aminotransferase; ARB  angiotensin receptor blocker; AST 
; CCB  calcium channel blocker; CHF  congestive heart failure;
CV electrical cardioversion; GI gastrointestinal; Hb hemoglobin;
serum glutamic oxaloacetic transaminase; SGPT serum glutamic
tagonist., PCV,
ban
0)
00)
.2)
7)
0)
.7)
133)
 ala
ressure
ance; ESAS Institute, Inc., Cary, North Carolina).
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Patient characteristics. Among the 14,264 patients ran-
domized in ROCKET AF, follow-up was complete in
99.9% of patients (32 patients were lost to follow-up). The
median patient age at randomization was 73 years, the
median CHADS2 score was 3.0, 52% had prior stroke or
TIA, and 81% had persistent AF. As shown in Table 1,
patients who underwent cardioversion or AF ablation were
younger (median age: 69), more often white, and more
commonly had paroxysmal AF, a higher prevalence of sleep
apnea, and were more frequently taking amiodarone or
another antiarrhythmic agent. Patient characteristics were
similar among patients who did and did not undergo
cardioversion or ablation in the 2 treatment arms (rivaroxa-
ban vs. warfarin).
Incidence and predictors of cardioversion and catheter
ablation. Over a median follow-up of 2.1 years (1.6 [25th
percentile], 2.4 [75th percentile]) years, 321 patients had a
total of 460 on randomized treatment cardioversion or AF
ablation procedures. A total of 143 patients underwent 181
ECV procedures (119 had only 1, 14 had 2, 7 had 3, 2 had
4, and 1 patient had 5 procedures), 142 patients underwent
194 PCV procedures (113 with 1, 20 with 2, 3 with 3, 2
with 4, 3 with 5, and 1 with 9), and 79 patients underwent
85 AF ablation procedures. Among the patients undergoing
AF ablation, only 6 (7.6%) underwent repeat ablation.
During the trial, the overall incidence of ECV, PCV, or AF
ablation was 1.45 per 100 patient-years (n  321). As
shown in Figure 1 and Table 2, the rate of ECV, PCV, or
AF ablation was 1.44 per 100 patient-years (n 161) in the
warfarin arm and 1.46 per 100 patient-years in the rivar-
oxaban arm (n  160). On the day of ECV, PCV, or AF
Figure 1
Cumulative Incidence of Electrical Cardioversion,
Pharmacologic Cardioversion,
or Catheter Ablation According to Treatment Assignment
Electrical cardioversion, pharmacologic cardioversion, or
catheter ablation by randomized treatment (warfarin or rivaroxaban).ablation, 256 of 321 patients (80%) were taking randomized
treatment, including 39 of 79 (49%) AF ablation patients,
120 of 143 (84%) ECV patients, and 129 of 142 (91%) PCV
patients. Only 24 patients (rivaroxaban n  12, warfarin
n 12) received low-molecular-weight heparin within 24 h
of ECV, PCV, or ablation. The composite rates of ECV,
PCV, or AF ablation were greatest in North America and
Incidence of ECV, PCV, and AF AblationTable 2 Incidence of ECV, PCV, and AF Ablation
Endpoint
Events per
100 Patient Yrs
(Total Events) HR (95% CI) p Value
ECV
Overall 0.64 (143)
Randomized treatment
Warfarin 0.60 (67) 1.00 —
Rivaroxaban 0.69 (76) 1.15 (0.83–1.60) 0.398
Region 0.001
Western Europe 1.23 (39) 1.00 —
Asia/Pacific islands 0.09 (3) 0.07 (0.02–0.24) 0.001
Eastern Europe 0.41 (35) 0.34 (0.21–0.53) 0.001
Latin America 0.14 (4) 0.11 (0.04–0.32) 0.001
North America 1.42 (62) 1.20 (0.81–1.80) 0.365
PCV
Overall 0.64 (142)
Randomized treatment
Warfarin 0.63 (71) 1.00 —
Rivaroxaban 0.64 (71) 1.01 (0.73–1.41) 0.936
Region 0.001
Western Europe 0.72 (23) 1.00 —
Asia/Pacific islands 0.09 (3) 0.13 (0.04–0.43) 0.001
Eastern Europe 1.05 (90) 1.50 (0.95–2.37) 0.083
Latin America 0.07 (2) 0.10 (0.02–0.40) 0.001
North America 0.54 (24) 0.81 (0.45–1.43) 0.459
Ablation
Overall 0.35 (79)
Randomized treatment
Warfarin 0.38 (43) 1.00 —
Rivaroxaban 0.32 (36) 0.85 (0.55–1.33) 0.476
Region 0.001
Western Europe 0.50 (16) 1.00 —
Asia/Pacific islands 0.06 (2) 0.12 (0.03–0.53) 0.005
Eastern Europe 0.24 (21) 0.49 (0.25–0.94) 0.031
Latin America 0.14 (4) 0.28 (0.09–0.85) 0.024
North America 0.81 (36) 1.68 (0.93–3.03) 0.084
Cardioversion or ablation
Overall 1.45 (321)
Randomized treatment
Warfarin 1.44 (161) 1.00 —
Rivaroxaban 1.46 (160) 1.01 (0.81–1.26) 0.934
Region 0.001
Western Europe 2.10 (66) 1.00 —
Asia/Pacific islands 0.24 (8) 0.12 (0.06–0.24) 0.001
Eastern Europe 1.64 (139) 0.80 (0.59–1.07) 0.126
Latin America 0.35 (10) 0.17 (0.09–0.32) 0.001
North America 2.25 (98) 1.13 (0.83–1.55) 0.439
AF atrial fibrillation; CI confidence interval; ECV electrical cardioversion; HR hazard ratio;
CV  pharmacologic cardioversion; yrs  years.Western Europe (Fig. 2). The rates of ECV and AF
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May 14, 2013:1998–2006 Outcomes After Cardioversion and Atrial Fibrillation With Rivaroxabanablations were highest in North America, and PCV was
most frequent in Eastern Europe (Table 2).
In the multivariable model analysis, heart rate 80
beats/min, diastolic blood pressure 75 mm Hg, paroxys-
mal AF, and new-onset AF were associated with a higher
probability of ECV, PCV, or AF ablation (Table 3).
Multivariable Model of Factors AssociatedWith the Utilization of ECV, PCV, or AF AblationTable 3 Multivariable Model of Fac ors AssociatedWith the Utilization of ECV, PCV, or AF Ablation
Factor HR 95% CI p Value
Age, HR for 10-year increase 0.77 0.69–0.87 0.001
Region
Asia/Pacific Islands 0.13 0.06–0.27 0.001
Eastern Europe 0.68 0.50–0.92
Latin America 0.21 0.11–0.41
North America 1.11 0.80–1.53
Western Europe 1.00 —
Systolic BP, HR for 10-mm Hg increase 0.86 0.78–0.94 0.001
Heart rate, HR for 10-beats/min increase
Linear spline 80 0.82 0.72–0.93 0.001
Linear spline 80 1.19 1.07–1.32
Diastolic BP, HR for 10 mm Hg increase
Linear spline 75 1.70 1.24–2.35 0.004
Linear spline 75 0.84 0.67–1.06
Type of AF
Persistent 1.00 — 0.001
Paroxysmal 2.72 2.14–3.47
New 3.19 1.66–6.11
Sotalol 3.63 2.49–5.27 0.001
Amiodarone 2.65 1.96–3.60 0.001
Other antiarrhythmic drugs 2.85 1.87–4.34 0.001
Digoxin 0.62 0.47–0.82 0.001
Calcium channel blocker 1.38 1.08–1.76 0.009
Thienopyridine 2.02 1.10–3.71 0.024
Beta blocker 1.31 1.00–1.71 0.046
Figure 2
Cumulative Incidence of Electrical Cardioversion,
Pharmacologic Cardioversion,
or Catheter Ablation by Region
Electrical cardioversion, pharmacologic cardioversion, or catheter ablation by region.o
AF  atrial fibrillation; BP  blood pressure; CI  confidence interval; ECV  electrical cardiover-
sion; HR  hazard ratio; PCV  pharmacologic cardioversion.Similarly, sotalol, amiodarone, other antiarrhythmic therapy,
calcium channel blockade, beta-blockade, and thienopyridine
use were all associated with a higher probability of ECV, PCV,
or catheter ablation. Conversely, global region (outside North
America or Western Europe), older age, increasing systolic
blood pressure, heart rate80 beats/min, and digoxin use were
associated with lower rates of ECV, PCV, or AF ablation. As
illustrated in Table 4, predictors of cardioversion alone (ECV
or PCV) following multivariable adjustment were similar.
30-day outcomes following cardioversion or AF ablation.
As shown in Table 5, there were no stroke or systemic
embolism events before intervention in those patients who
underwent cardioversion or ablation. The risk of stroke or
death in the first 30 days after ECV, PCV, or AF was
increased despite the low absolute numbers of events (n 
strokes or systemic emboli and n  4 all-cause deaths).
verall, in the first 30 days after ECV, PCV, or AF
blation, the rate of stroke or systemic emboli was 0.93%
nd the mortality rate was 1.25%. The rate of major and
on-major clinically relevant bleeding in the first 30 days
fter ECV, PCV, or AF ablation was 2.18% compared with
.97% at baseline (Table 5).
ong-term outcomes following cardioversion or AF
blation. Longer-term outcomes (30 days) after ECV,
CV, or AF ablation are also shown in Table 5. When
xamining the time to first event, the hazards for stroke or
ystemic embolism, cardiovascular death, all-cause death,
he composite of stroke, systemic embolism or cardiovascu-
ar death, and the composite of stroke, systemic embolism,
Multivariable Model ofFac ors Associated With ECV or PCVTable 4 Mul ivariable Model ofFactors Associated With ECV or PCV
Factor HR 95% CI p Value
Age, HR for 10-year increase 0.79 0.69–0.90 0.001
Region
Asia/Pacific Islands 0.12 0.05–0.27 0.001
Eastern Europe 0.75 0.54–1.05
Latin America 0.16 0.07–0.37
North America 1.09 0.76–1.55
Western Europe 1.00 —
Heart rate, HR for 10-beats/min increase
Linear spline 80 0.81 0.71–0.94 0.003
Linear spline 80 1.18 1.06–1.32
Systolic BP, HR for 10-mm Hg increase 0.85 0.77–0.93 0.001
Diastolic BP, HR for 10-mm Hg increase 1.15 0.98–1.34 0.088
Type of AF
Persistent 1.00 — 0.001
Paroxysmal 3.05 2.34–3.98
New 3.15 1.52–6.52
Sotalol 3.53 2.34–5.33 0.001
Amiodarone 2.41 1.73–3.35 0.001
Other antiarrhythmic drugs 2.98 1.93–4.61 0.001
Digoxin 0.57 0.42–0.78 0.001
Calcium channel blocker 1.43 1.10–1.86 0.007
AF  atrial fibrillation; BP  blood pressure; CI  confidence interval; HR  hazard ratio. ECV 
lectrical cardioversion; PCV  pharmacologic cardioversion.r all-cause death were not statistically different before and
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available follow-up. In the 79 patients who underwent AF
ablation, no strokes were observed on treatment; however, 1
patient (n  1 of 79, 1.3%) suffered a stroke off-treatment
not taking randomized study medication).
andomized treatment and outcomes following cardio-
ersion or AF ablation. The hazards of hospitalization
HR: 2.01; 95% CI: 1.51 to 2.68, p  0.0001) and major
and non-major clinically relevant bleeding (HR: 1.51; 95%
CI: 1.12 to 2.05, p  0.0072) were greater following ECV,
CV, or AF ablation. Among the hospitalization events,
1% (n  11) were elective, 22% were urgent (n  22), and
6% (n  65) were emergent. Causes for hospitalization
ncluded bleeding (11%; n  11), acute coronary syndrome
1%; n  1), non-CNS embolism (1%; n  1), stroke (1%;
 1), TIA (1%; n 1), elective admission (11%; n 11),
and other adverse events (73%; n  72). In order to assess
modification of treatment effect according to cardioversion
or ablation procedures, interaction tests were performed.
Interaction terms for randomized treatment-by-cardioversion
or ablation were not significant for either hospitalization
Association Between ECV/PCV/AF Ablation and OutcomesTable 5 Association Between ECV/PCV/AF Ablation and Outco
Even
Even
Ti
Event Event Pre-Procedure 0–30
Stroke or systemic embolism 0 (0) 3 (0
CV death 0 (0) 4 (1
All-cause death 0 (0) 4 (1
Hospitalization† 121 (37.69) 12 (6
Stroke, systemic embolism, or CV death 0 (0) 7 (2
Stroke, systemic embolism, or all-cause death 0 (0) 7 (2
Major or NMCR bleeding† 32 (9.97) 6 (2
Event rates are shown as number of events (%). As these are raw percentages, they cannot be co
regression models that include all patients where cardioversion/ablation is included as a time-dep
pulmonary disease. Additionally, efficacy models are adjusted for prior stroke or transient ischem
failure, body mass index, region, alcohol use, diabetes, and creatinine; the bleeding model a
cardioversion/pharmacologic cardioversion/atrial fibrillation ablation and treatment  0.5792 fo
CV  cardiovascular; NMCR  non-major clinically relevant.
Outcomes After ECV, PCV, or CatheterAblation According to Rand mized Tr atmentTable 6 Outcomes After E V, PCV, or CatheterAblation According to Randomized Treatment
Endpoint Following ECV,
PCV, or Ablation
Rivaroxaban
(N  160)
Warfarin
(N  161)
All
(N  321)
Stroke or systemic embolism 3 (1.88) 3 (1.86) 6 (1.87)
CV death 2 (1.25) 4 (2.48) 6 (1.87)
All-cause death 3 (1.88) 6 (3.73) 9 (2.80)
Hospitalization 50 (31.25) 48 (29.81) 98 (30.53)
Stroke or systemic embolism
or CV death
5 (3.13) 7 (4.35) 12 (3.74)
Stroke or systemic embolism
or death from any cause
6 (3.75) 9 (5.59) 15 (4.67)
Major or NMCR bleeding 30 (18.75) 21 (13.04) 51 (15.89)
Values are numbers of events following cardioversion or ablation; percentages of patients with
cardioversion or ablation in the given treatment group are shown in parentheses.CV  cardiovascular; ECV  electrical cardioversion; NMCR  non-major clinically relevant;
PCV  pharmacologic cardioversion.(p  0.5792) or major or non-major clinically relevant
bleeding (p  0.4590). As shown in Table 6, individual event
ounts were similar between the rivaroxaban- and warfarin-
reated patients following ECV, PCV, or AF ablation. After
CV, PCV, or ablation, the rate of stroke or systemic
mbolism was 1.88% (n  3) in the rivaroxaban arm and
.86% (n  3) in the warfarin arm. In terms of all-cause
eath, the rate was 1.88% (n  3) in the rivaroxaban arm
ersus 3.73% (n  6) in the warfarin arm. When we
estricted this analysis to only those patients who were
aking the study drug on the day of the procedure, the
esults were similar (Table 7).
iscussion
estoration of sinus rhythm in patients with symptomatic
r hemodynamically significant AF can improve cardiovas-
ular hemodynamics, functional status, and quality of life
10,11). However, all means of restoring sinus rhythm,
ncluding cardioversion and AF ablation carry a transient
-procedure in
Patients at
Procedure
Event Post-procedure
Regardless of Whether
an Event Occurred
Pre-Procedure
>30 days 0–30 days >30 days HR (95% CI)* p Value
3 (0.93) 3 (0.93) 3 (0.93) 1.38 (0.61–3.11) 0.4423
2 (0.62) 4 (1.25) 2 (0.62) 1.57 (0.69–3.55) 0.2793
5 (1.56) 4 (1.25) 5 (1.56) 1.75 (0.90–3.42) 0.0990
38 (19.0) 22 (6.85) 76 (23.68) 2.01 (1.51–2.68) 0.0001
5 (1.56) 7 (2.18) 5 (1.56) 1.53 (0.86–2.72) 0.1507
8 (2.49) 7 (2.18) 8 (2.49) 1.64 (0.98–2.75) 0.0605
39 (13.49) 7 (2.18) 44 (13.71) 1.51 (1.12–2.05) 0.0072
d directly. *Hazard ratios (HR) and confidence intervals (CI) come from Cox proportional hazards
t covariate. All models are adjusted for sex, age, diastolic blood pressure, and chronic obstructive
k, estimated glomerular filtration rate, vascular disease, type of AF, heart rate, congestive heart
lly adjusts for gastrointestinal bleeding, aspirin, and anemia. †Interaction between electrical
alization and 0.4590 for major or non-major clinically relevant bleeding.
Outcomes after ECV, PCV,or Cath ter Ablation Among ThoseTaking S udy Drug on the Day f Procedure
Table 7
Outcomes after ECV, PCV,
or Catheter Ablation Among Those
Taking Study Drug on the Day of Procedure
Endpoint Following ECV,
PCV, or Ablation
Rivaroxaban
(N  124)
Warfarin
(N  121)
All
(N  245)
Stroke or systemic embolism 2 (1.61) 3 (2.48) 5 (2.04)
CV death 0 (0) 2 (1.65) 2 (0.82)
All-cause death 1 (0.81) 4 (3.31) 5 (2.04)
Hospitalization 40 (32.26) 37 (30.58) 77 (31.43)
Stroke or systemic embolism
or CV death
2 (1.61) 5 (4.13) 7 (2.86)
Stroke or systemic embolism
or death from any cause
3 (2.42) 7 (5.79) 10 (4.08)
Major or NMCR bleeding 24 (19.35) 17 (14.05) 41 (16.73)
Values are numbers of events following cardioversion or ablation; percentages of patients taking
study drug on the day of cardioversion or ablation in the given treatment group are shown in
parentheses.mes
t Post
t-Free
me of
days
.93)
.25)
.25)
.0)
.18)
.18)
.08)
mpare
enden
ic attac
dditionaCV  cardiovascular; ECV  electrical cardioversion; NMCR  non-major clinically relevant;
PCV  pharmacologic cardioversion.
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May 14, 2013:1998–2006 Outcomes After Cardioversion and Atrial Fibrillation With Rivaroxabanincrease in thrombotic risk (2,12). While there is a wealth of
data for cardioversion and AF ablation in patients treated
with warfarin, there are limited data and clinical experience
regarding restoration of sinus rhythm in patients being
treated with direct, oral factor Xa inhibitors such as rivar-
oxaban. In this study of moderate- to high-risk patients
with non-valvular AF, there was no significant difference in
long-term outcomes following cardioversion or AF ablation.
Additionally, outcomes following ECV, PCV, or AF abla-
tion were similar in those patients treated with rivaroxaban
or warfarin.
It is important to recognize that patients who underwent
cardioversion or catheter ablation in ROCKET AF were at
moderate to high risk of stroke due to the inclusion criteria
for the trial. Additionally, by protocol, patients with plans
for elective cardioversion or restoration of sinus rhythm
during screening were excluded from enrolling in
ROCKET AF. Consequently, a significant majority (81%)
of patients in the ROCKET AF trial had persistent AF.
However, following study entry, patients who required
cardioversion due to hemodynamic instability, progressive
heart failure, or refractory symptoms despite optimal med-
ical therapy could undergo cardioversion or AF ablation per
study protocol. Despite a relatively selected, high-risk pop-
ulation, we found no evidence of increased rates of stroke or
systemic embolism or mortality in long-term follow-up among
those who underwent procedures for restoration of sinus
rhythm. While there is evidence of transient increases in risk
after ECV, PCV, and AF ablation, our findings provide
reassurance that the risk of stroke is successfully mitigated in
the long term with post-procedural oral anticoagulation.
In contrast to the above findings, we observed increased
rates of hospitalization following cardioversion or AF abla-
tion. Increased hospitalization has been observed in other
studies of rhythm management, including the AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
Management) trial (13). In the AFFIRM trial, cardiover-
sion was associated with a 6-fold increase in cardiac hospi-
talization (39.3% vs. 5.8%) compared with the 2-fold
increase observed in the ROCKET AF study. Most of the
hospitalizations following cardioversion or AF ablation were
for non-cardiovascular causes, and most were emergent.
The potential reasons for an increased rate of hospitalization
are many and include the confounding associated with a
post-randomization variable. For example, patients who
become ill and require restoration of sinus rhythm may very
well have an increased risk of hospitalization independent of
the procedure. Future studies should investigate the causes
for hospitalization after cardioversion or AF ablation, and
how the risk of admission/readmission may be modified or
avoided.
While professional society guidelines recommend resto-
ration of sinus rhythm in patients with AF complicated by
hemodynamic impairment or in patients with impaired
quality of life despite adequate rate control (1,10), the use of
cardioversion and AF ablation in clinical practice is variable(14). In this study of more than 14,000 patients across 45
countries, we found significant regional variation in the use
of cardioversion and AF ablation. These regional differences
likely reflect differences in standard local practice, as well as
differing perspectives regarding the risks and benefits of
restoring and maintaining sinus rhythm. Additionally, these
differences may also reflect availability. In the United States,
decreased availability of cardioversion during weekend ad-
missions has been associated with increased length of stay
and cost (15). Similar to the variation in the use of
rhythm-control therapies, recent data from the international
RE-LY AF (Randomized Evaluation of Long-term antico-
agulant therapy) registry also demonstrate significant inter-
national variation in oral anticoagulation, stroke rates, and
mortality in patients with AF (16). Future studies should
investigate the reasons behind variation and whether treat-
ment differences are linked to differential outcomes.
Several retrospective, observational studies have sug-
gested that the risk of stroke after catheter ablation of AF is
low (12) and that long-term anticoagulation, even in mod-
erate to high-risk patients, may not be necessary (17).
owever, in contrast to these studies, we found that the
ong-term risk of stroke or systemic embolism following
estoration of sinus rhythm was substantial (1.86 events per
00 patient-years) despite anticoagulant therapy.
While these data represent the first reported experience
ith cardioversion or AF ablation in patients treated with
ral factor Xa inhibition, there are published data regarding
ardioversion in patients treated with oral direct thrombin
nhibition. An analysis of outcomes following cardioversion
n the RE-LY trial demonstrated no difference in stroke or
ystemic embolism or major bleeding at 30 days in patients
reated with dabigatran 150 mg twice daily versus dose-
djusted warfarin (3). Due to differences in trial design
including higher baseline risks of the patients and higher
roportion with persistent AF in ROCKET AF) as well as
ifferences in blinding, cardioversion and AF ablation were
ess frequent in ROCKET AF. However, consistent with
he findings from RE-LY, we found no evidence of an
ncreased risk of stroke or systemic embolism in patients
reated with a novel oral anticoagulant in ROCKET AF
rivaroxaban) compared with warfarin. When comparing
he rates of stroke or systemic embolism at 30 days, 0.3% of
he dabigatran 150 mg-treated patients and 0.6% of the
arfarin-treated patients in the RE-LY trial experienced a
troke after cardioversion compared with 0.9% in the
oderate- to high-risk population in ROCKET AF.
tudy limitations. First, this analysis was a post hoc
analysis of prospectively collected clinical trial data. Further-
more, given the post-randomization nature of cardioversion
or AF ablation, we cannot completely exclude the possibility
that confounding influenced the comparisons. Second,
given the trial design, cardioversion and AF ablation were
relatively uncommon events. Therefore, our sample size and
power to detect small differences in outcomes were limited.
Finally, cardioversion procedures are often guided by trans-
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Outcomes After Cardioversion and Atrial Fibrillation With Rivaroxaban May 14, 2013:1998–2006esophageal echocardiography; however, data on the use and
findings of transesophageal echocardiography were not col-
lected. On the other hand, these data represent the first
international experience of long term outcomes following
restoration of sinus rhythm in patients treated with an
anti-Xa inhibitor.
Clinical implications. First, treated patients receiving oral
anticoagulation do not appear to be at excessive risk of
stroke or systemic embolism in the long term following
cardioversion or AF ablation. Therefore, clinicians should
follow guideline recommendations and ensure adequate
anticoagulation in moderate- to high-risk patients. Thera-
peutic anticoagulation is required before and after cardio-
version, regardless of vitamin K antagonism or the use of
factor Xa inhibition. While we found no evidence of
differential outcomes according to treatment with rivaroxa-
ban or warfarin, these questions will ultimately require
testing in dedicated clinical trials of novel oral anticoagula-
tion surrounding cardioversion and catheter ablation. Cau-
tion should be exercised when using raw event rates to draw
clinical inferences about post-randomization management
strategies.
Conclusions
There are limited data and clinical experience regarding
restoration of sinus rhythm in patients being treated with
direct, oral factor Xa inhibitors. In this study of moderate-
to high-risk patients with non-valvular AF, there was
significant regional variation in the use of procedures for the
restoration and maintenance of sinus rhythm. In the overall
trial population, despite an increase in hospitalization, there
was no significant difference in long-term stroke rates or
survival following cardioversion or AF ablation. Finally, out-
comes following ECV, PCV, or AF ablation were similar in
those patients treated with rivaroxaban or warfarin.
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